New York, February 17, 2026, 11:23 (EST) — Regular session
- UnitedHealth slipped 0.8% in late morning trading, trailing other managed-care stocks.
- The report pointed to CEO Stephen Hemsley’s private startup bets, raising questions about possible conflicts.
- Medicare Advantage rate deadlines loom, while enrollment growth remains sluggish and in the spotlight.
UnitedHealth Group Incorporated (UNH) dropped 0.8%, trading at $290.89 as of 11:23 a.m. ET Tuesday. The move came after a Wall Street Journal report revealed CEO Stephen Hemsley had poured tens of millions into healthcare startups via his own Cloverfields Capital. Some of these firms either compete with or count UnitedHealth as a client. According to UnitedHealth’s statement to the Journal, Hemsley “continues to comply fully with UnitedHealth Group’s conflict of interest and trading policies.” The company also told the paper Hemsley has shifted his personal healthcare investments into a trust overseen by independent trustees. 1
The governance news knocked UnitedHealth hard, with shares diving almost 19% on Jan. 27. The stock, already jittery about Washington and mounting costs, took another hit as the company projected lower 2026 revenue and federal officials proposed a barely changed Medicare Advantage rate for 2027. “Investors hoping for a quick turnaround may have to wait longer than hoped,” Morningstar analyst Julie Utterback said at the time. 2
Medicare Advantage keeps delivering for major insurers, with close to 35.5 million enrolled as of Feb. 1—a roughly 3% rise from last year. Yet, sign-ups during the Oct. 15–Dec. 7 window increased just 1%, according to federal figures reported by STAT. 3
Delaware law demands that directors prioritize the company’s interests, flagging any conflicts before making moves. UnitedHealth’s board policy is explicit: directors should steer clear of relationships that might conflict with the company unless they come clean about it and measures are in place to keep those conflicts from swaying judgment. 4
UnitedHealth grabbed attention in an otherwise flat batch. Humana tacked on roughly 0.6%, Cigna edged up 0.3%. Elevance Health dipped 0.4%. The S&P 500 nudged higher.
Cost pressure remains the main theme here. On Tuesday, STAT reported that UnitedHealth executives have committed to leveraging artificial intelligence to slash $1 billion in costs this year. Hemsley described it as the company “clearly embarking on a new age of technology” for health care. 5
UnitedHealth turned in its 2025 revenue numbers in late January, coming in at $447.6 billion. The company also laid out revenue guidance for 2026—management’s projecting more than $439 billion, with adjusted earnings topping $17.75 per share. Executives said this move reflects a broader effort to cut back on complexity and enforce stricter financial controls. 6
Still, if the CEO’s investment keeps looking like optics and doesn’t translate into real action, the stock’s dip might not stick. On the flip side, things could get complicated: investors might push for more details about the trust and how, if at all, it intersects with UnitedHealth’s other business. Then there’s Medicare Advantage pricing—always lurking as a risk—capable of squeezing margins, driving exits, or fueling benefit cuts.
The calendar is tight. CMS set a Feb. 25, 11:59 p.m. ET deadline for comments on its 2027 Medicare Advantage advance notice, with the final rate slated to drop by April 6. Eyes are also on any company filings or board moves that might clarify Hemsley’s external investments or the structure of the trust. 7
